What to do with a patient with nocturnal enuresis who has shown improvement on imipramine (tricyclic antidepressant) 25 mg but relapses when the medication is stopped after 5 months?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Imipramine-Responsive Nocturnal Enuresis with Relapse After Discontinuation

Continue imipramine treatment for a total duration of 4-6 months from initiation, then implement a gradual taper with scheduled drug holidays rather than abrupt discontinuation to minimize relapse risk. 1

Current Treatment Duration and Next Steps

Since the patient has been on imipramine for 5 months with good response but relapses upon discontinuation, you are approaching the recommended treatment endpoint but have not yet completed the full course:

  • Standard imipramine treatment duration for enuresis is 4-6 months when effective 1
  • At 5 months, you are within the appropriate treatment window 1
  • The relapse you observed is expected—imipramine has a relapse rate as high as 50% upon discontinuation 1

Recommended Tapering Strategy

Do not abruptly stop imipramine; instead, implement a structured discontinuation protocol:

  • Taper to the lowest effective dose gradually rather than stopping abruptly 2
  • Institute regular drug holidays of at least 2 weeks every third month to decrease tolerance risk 2
  • The FDA label specifically states "dosage should be tapered off gradually rather than abruptly discontinued; this may reduce the tendency to relapse" 3

Important Caveat About Relapse

Children who relapse when imipramine is discontinued do not always respond to a subsequent course of treatment 3. This is a critical consideration—the current response may not be reproducible if you stop and restart.

Alternative Strategies if Relapse Persists

If the patient continues to relapse despite proper tapering:

  • Consider transitioning to an enuresis alarm, which has a 66% success rate with more than half experiencing long-term success and appears more durable than pharmacotherapy 4, 5
  • Alarms are associated with one fewer wet night per week compared to imipramine after treatment discontinuation 5
  • Combination therapy with desmopressin may be added to imipramine if there is partial response, provided fluid intake is restricted during evening and night 2
  • For truly refractory cases after alarm and desmopressin failure, combination of solifenacin with low-dose imipramine (25 mg) has shown efficacy with lower relapse rates 6

Safety Monitoring Considerations

Given the 5-month treatment duration, ensure:

  • ECG monitoring should have been performed before treatment initiation and periodically thereafter due to cardiac arrhythmia risk 1
  • Secure medication storage away from younger siblings, as accidental ingestion can be fatal 1, 2
  • The current 25 mg dose is appropriate and should not exceed 2.5 mg/kg/day 3

Why Not Just Continue Indefinitely?

While maintenance beyond 6 months might seem logical, the guidelines specifically recommend 4-6 months of treatment 1, and imipramine should only be used as third-line therapy due to safety concerns 2. The goal is to achieve sustained remission with the shortest necessary treatment duration, followed by transition to safer long-term strategies like behavioral interventions if needed.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Imipramine Therapy for Childhood Enuresis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment Options for Enuresis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Tricyclic and related drugs for nocturnal enuresis in children.

The Cochrane database of systematic reviews, 2000

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.